Q0113 – Pinworm examinations

Long description

Pinworm examinations

Short description

Pinworm examinations

Pricing indicator

21 Clinical Lab Fee Schedule – national limitation amount

Medicare coverage

C Carrier judgment – coverage decided by the Medicare contractor

BETOS category

T1H Lab tests - other (Non-Medicare fee schedule)

Added

January 1, 1994

Last change

January 1, 1994 – No change

Nearby Q codes

• Q0081 – Infusion therapy, using other than chemotherapeutic drugs, per visit
• Q0083 – Chemotherapy administration by other than infusion technique only (e.g., subcutaneous, intramuscular, push), per visit
• Q0084 – Chemotherapy administration by infusion technique only, per visit
• Q0085 – Chemotherapy administration by both infusion technique and other technique(s) (e.g., subcutaneous, intramuscular, push), per visit
• Q0091 – Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory
• Q0092 – Set-up portable x-ray equipment
• Q0111 – Wet mounts, including preparations of vaginal, cervical or skin specimens
• Q0112 – All potassium hydroxide (koh) preparations
• Q0114 – Fern test
• Q0115 – Post-coital direct, qualitative examinations of vaginal or cervical mucous
• Q0138 – Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)
• Q0139 – Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (for esrd on dialysis)
• Q0144 – Azithromycin dihydrate, oral, capsules/powder, 1 gram
• Q0155 – Dronabinol (syndros), 0.1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
• Q0161 – Chlorpromazine hydrochloride, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
• Q0162 – Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen